Rescue of hypovitaminosis a induces non-amyloidogenic amyloid precursor protein (APP) processing

Current Alzheimer Research

Volumn 13, Issue 11, 2016, Pages 1277-1289

  Reinhardt, Sven ^a   Grimm, Marcus O W ^b   Stahlmann, Christoph ^b   Hartmann, Tobias ^b   Shudo, Koichi ^c   Tomita, Taisuke ^d   Endres, Kristina ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c Kawasaki   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

A beta peptides; Alpha secretase; Alzheimer s disease; Nuclear receptor; Retinoic acid; Shedding; Vitamin A

Indexed keywords

ADAM10 ENDOPEPTIDASE; ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; ETRETIN; PROTEINASE; RE 80; RETINOIC ACID DERIVATIVE; TAMIBAROTENE; TP 80; TZ 325; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN[1-40]; KERATOLYTIC AGENT; PEPTIDE FRAGMENT; PRESENILIN 2; PSEN2 PROTEIN, HUMAN; RETINOIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME ACTIVITY; FEMALE; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MALE; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; NUTRITIONAL STATUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SECRETION; RAT; RETINOL DEFICIENCY; WILD TYPE; ANIMAL; BRAIN CORTEX; CELL CULTURE; CHEMISTRY; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; GENE REGULATORY NETWORK; GENETICS; METABOLISM; NERVE CELL; NEUROBLASTOMA; NEWBORN; WISTAR RAT;

ACITRETIN; ADAM10 PROTEIN; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; FEMALE; GENE REGULATORY NETWORKS; HUMANS; KERATOLYTIC AGENTS; MICE; NEUROBLASTOMA; NEURONS; PEPTIDE FRAGMENTS; PRESENILIN-2; RATS, WISTAR; TRETINOIN; VITAMIN A DEFICIENCY;

EID: 84995743337     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205013666160603002105     Document Type: Article

References (81)

1. Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885-890 (1984).
2. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286(5440): 735-741 (1999).
3. Tosto G, Reitz C. Genome-wide association studies in Alzheimer’s disease: a review. Curr. Neurol Neurosci Rep 13: 381 (2013).
4. Bali J, Gheinani AH, Zurbriggen S, Rajendran L. Role of genes linked to sporadic Alzheimer’s disease risk in the production of beta-amyloid peptides. Proc Natl Acad Sci USA 109: 15307-15311 (2012).
5. Mohajeri MH, Troesch B, Weber P. Inadequate supply of vitamins and DHA in the elderly: implications for brain aging and Alzheimer-type dementia. Nutrition 31: 261-275 (2015).
6. Swaminathan A, Jicha GA. Nutrition and prevention of Alzheimer’s dementia. Front Aging Neurosci 6: 282 (2014).
7. Farina N, Isaac MG, Clark AR, Rusted J, Tabet N. Vitamin E for Alzheimer’s dementia and mild cognitive impairment. Cochrane Database Syst Rev 11: CD002854 (2012).
8. Vitamin E: Curse or benefit in Alzheimer’s disease? A systematic investigation of the impact of α, ƴ – and δ - tocopherol on Aβ generation and degradation in neuroblastoma cells. J Nutr Health Aging 19(6): 646-656 (2015)
9. Lopes da Silva S, Vellas B, Elemans S, Luchsinger J, Kamphuis P, Yaffe K, et al. Plasma nutrient status of patients with Alzheimer’s disease: Systematic review and meta-analysis. Alzheimers Dement 10: 485-502 (2014).
10. Goodman AB. Retinoid receptors, transporters, and metabolizers as therapeutic targets in late onset Alzheimer disease. J Cell Physiol 209: 598-603 (2006).
11. Goodman AB, Pardee AB. Evidence for defective retinoid transport and function in late onset Alzheimer’s disease. Proc Natl Acad Sci USA 100: 2901-2905 (2003).
12. Zhao J, Fu Y, Liu CC, Shinohara M, Nielsen HM, Dong Q, et al. Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway. J Biol Chem 289: 11282-11292 (2014).
13. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335: 1503-1506 (2012).
14. Goncalves MB, Clarke E, Hobbs C, Malmqvist T, Deacon R, Jack J, et al. Amyloid beta inhibits retinoic acid synthesis exacerbating Alzheimer disease pathology which can be attenuated by an retinoic acid receptor alpha agonist. Eur J Neurosci 37: 1182-1192 (2013).
15. Melino G, Draoui M, Bernardini S, Bellincampi L, Reichert U, Cohen P. Regulation by retinoic acid of insulin-degrading enzyme and of a related endoprotease in human neuroblastoma cell lines. Cell Growth Differ 7: 787-796 (1996).
16. Prinzen C, Muller U, Endres K, Fahrenholz F, Postina R. Genomic structure and functional characterization of the human ADAM10 promoter. FASEB J 19: 1522-1524 (2005).
17. Tippmann F, Hundt J, Schneider A, Endres K, Fahrenholz F. Upregulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J 23: 1643-1654 (2009).
18. Kitaoka K, Shimizu N, Ono K, Chikahisa S, Nakagomi M, Shudo K, et al. The retinoic acid receptor agonist Am80 increases hippocampal ADAM10 in aged SAMP8 mice. Neuropharmacology 72: 58-65 (2013).
19. Kapoor A, Wang BJ, Hsu WM, Chang MY, Liang SM, Liao YF. Retinoic acid-elicited RARalpha/RXRalpha signaling attenuates Abeta production by directly inhibiting gamma-secretase-mediated cleavage of amyloid precursor protein. ACS Chem Neurosci 4: 1093-1100 (2013).
20. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Vitamin A exhibits potent antiamyloidogenic and fibrildestabilizing effects in vitro. Exp Neurol 189: 380-392 (2004).
21. Takasaki J, Ono K, Yoshiike Y, Hirohata M, Ikeda T, Morinaga A, et al. Vitamin A has anti-oligomerization effects on amyloid-beta in vitro. J Alzheimers Dis 27: 271-280 (2011).
22. Endres K, Fahrenholz F, Lotz J, Hiemke C, Teipel S, Lieb K, et al. Increased CSF APPs-alpha levels in patients with Alzheimer disease treated with acitretin. Neurology 83: 1930-1935 (2014).
23. Endres K, Fahrenholz F. Upregulation of the alpha-secretase ADAM10--risk or reason for hope? FEBS J 277: 1585-1596 (2010).
24. Shudo K, Fukasawa H, Nakagomi M, Yamagata N. Towards retinoid therapy for Alzheimer’s disease. Curr. Alzheimer Res 6: 302-311 (2009).
25. Mingaud F, Mormede C, Etchamendy N, Mons N, Niedergang B, Wietrzych M, et al. Retinoid hyposignaling contributes to agingrelated decline in hippocampal function in short-term/working memory organization and long-term declarative memory encoding in mice. J Neurosci 28: 279-291 (2008).
26. Corcoran JP, So PL, Maden M. Disruption of the retinoid signalling pathway causes a deposition of amyloid beta in the adult rat brain. Eur J Neurosci 20: 896-902 (2004).
27. Buxbaum JN, Roberts AJ, Adame A, Masliah E. Silencing of murine transthyretin and retinol binding protein genes has distinct and shared behavioral and neuropathologic effects. Neuroscience 275: 352-364 (2014).
28. Shahar S, Lee LK, Rajab N, Lim CL, Harun NA, Noh MF, et al. Association between vitamin A, vitamin E and apolipoprotein E status with mild cognitive impairment among elderly people in low-cost residential areas. Nutr Neurosci 16: 6-12 (2013).
29. Ebisawa M, Ohta K, Kawachi E, Fukasawa H, Hashimoto Y, Kagechika H. Novel retinoidal tropolone derivatives. Bioisosteric relationship of tropolone ring with benzoic acid moiety in retinoid structure. Chem Pharm Bull (Tokyo) 49: 501-503 (2001).
30. Kagechika H, Kawachi E, Hashimoto Y, Shudo K. Retinobenzoic acids. 2. Structure-activity relationships of chalcone-4-carboxylic acids and flavone-4’-carboxylic acids. J Med Chem 32: 834-840 (1989).
31. Fukumoto H, Tomita T, Matsunaga H, Ishibashi Y, Saido TC, Iwatsubo T. Primary cultures of neuronal and non-neuronal rat brain cells secrete similar proportions of amyloid beta peptides ending at A beta40 and A beta42. Neuroreport 10: 2965-2969 (1999).
32. Cai Y, Dai T, Ao Y, Konishi T, Chuang KH, Lue Y, et al. Cytochrome P450 genes are differentially expressed in female and male hepatocyte retinoid X receptor alpha-deficient mice. Endocrinology 144: 2311-2318 (2003).
33. Marchetti MN, Sampol E, Bun H, Scoma H, Lacarelle B, Durand A. In vitro metabolism of three major isomers of retinoic acid in rats. Intersex and interstrain comparison. Drug Metab Dispos 25: 637-646 (1997).
34. Klein-Szanto AJ, Clark JN, Martin DH. Sexual differences in the distribution of epithelial alterations in vitamin A-deficient rats. Int J Vitam Nutr Res 50: 61-69 (1980).
35. Gieng SH, Raila J, Rosales FJ. Accumulation of retinol in the liver after prolonged hyporetinolemia in the vitamin A-sufficient rat. J Lipid Res 46: 641-649 (2005).
36. Jorissen E, Prox J, Bernreuther C, Weber S, Schwanbeck R, Serneels L, et al. The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex. J Neurosci 30: 4833-4844 (2010).
37. Steiner H, Kostka M, Romig H, Basset G, Pesold B, Hardy J, et al. Glycine 384 is required for presenilin-1 function and is conserved in bacterial polytopic aspartyl proteases. Nat Cell Biol 2: 848-851 (2000).
38. Weyer SW, Zagrebelsky M, Herrmann U, Hick M, Ganss L, Gobbert J, et al. Comparative analysis of single and combined APP/APLP knockouts reveals reduced spine density in APP-KO mice that is prevented by APPsalpha expression. Acta Neuropathol Commun 2: 36 (2014).
39. Grimm MO, Grosgen S, Riemenschneider M, Tanila H, Grimm HS, Hartmann T. From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer’s disease human post mortem brains and mice model via mass spectrometry. J Chromatogr A 1218: 7713-7722 (2011).
40. Mi H, Muruganujan A, Thomas PD. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res 41: D377-D386 (2013).
41. Endres K, Postina R, Schroeder A, Mueller U, Fahrenholz F. Shedding of the amyloid precursor protein-like protein APLP2 by disintegrin-metalloproteinases. FEBS J 272: 5808-5820 (2005).
42. Sherman BS. The effect of vitamin A on epithelial mitosis in vitro and in vivo. J Invest Dermatol 37: 469-480 (1961).
43. Kuwata T, Wang IM, Tamura T, Ponnamperuma RM, Levine R, Holmes KL, et al. Vitamin A deficiency in mice causes a systemic expansion of myeloid cells. Blood 95: 3349-3356 (2000).
44. Gottesman ME, Quadro L, Blaner WS. Studies of vitamin A metabolism in mouse model systems. Bioessays 23: 409-419 (2001).
45. Wagner E, Luo T, Drager UC. Retinoic acid synthesis in the postnatal mouse brain marks distinct developmental stages and functional systems. Cereb Cortex 12: 1244-1253 (2002).
46. Kurlandsky SB, Gamble MV, Ramakrishnan R, Blaner WS. Plasma delivery of retinoic acid to tissues in the rat. J Biol Chem 270: 17850-17857 (1995).
47. Norris AW, Cheng L, Giguere V, Rosenberger M, Li E. Measurement of subnanomolar retinoic acid binding affinities for cellular retinoic acid binding proteins by fluorometric titration. Biochim Biophys Acta 1209: 10-18 (1994).
48. Takase S, Ong DE, Chytil F. Transfer of retinoic acid from its complex with cellular retinoic acid-binding protein to the nucleus. Arch Biochem Biophys 247: 328-334 (1986).
49. Ruberte E, Friederich V, Chambon P, Morriss-Kay G. Retinoic acid receptors and cellular retinoid binding proteins. III. Their differential transcript distribution during mouse nervous system development. Development 118: 267-282 (1993).
50. Means AL, Thompson JR, Gudas LJ. Transcriptional regulation of the cellular retinoic acid binding protein I gene in F9 teratocarcinoma cells. Cell Growth Differ 11: 71-82 (2000).
51. Bellovino D, Morimoto T, Tosetti F, Gaetani S. Retinol binding protein and transthyretin are secreted as a complex formed in the endoplasmic reticulum in HepG2 human hepatocarcinoma cells. Exp Cell Res 222: 77-83 (1996).
52. Dries DR, Shah S, Han YH, Yu C, Yu S, Shearman MS, et al. Glu- 333 of nicastrin directly participates in gamma-secretase activity. J Biol Chem 284: 29714-29724 (2009).
53. Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, et al. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J 29: 3020-3032 (2010).
54. Longo FM, Massa SM. Neurotrophin receptor-based strategies for Alzheimer’s disease. Curr Alzheimer Res 2: 167-169 (2005).
55. Massa SM, Yang T, Xie Y, Shi J, Bilgen M, Joyce JN, et al. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J Clin Invest 120: 1774-1785 (2010).
56. Kane MA, Folias AE, Wang C, Napoli JL. Quantitative profiling of endogenous retinoic acid in vivo and in vitro by tandem mass spectrometry. Anal Chem 80: 1702-1708 (2008).
57. Rhinn M, Dolle P. Retinoic acid signalling during development. Development 139: 843-858 (2012).
58. Shearer KD, Stoney PN, Morgan PJ, McCaffery PJ. A vitamin for the brain. Trends Neurosci 35: 733-741 (2012).
59. Connor MJ, Sidell N. Retinoic acid synthesis in normal and Alzheimer diseased brain and human neural cells. Mol Chem Neuropathol 30: 239-252 (1997).
60. Fragoso YD, Shearer KD, Sementilli A, de Carvalho LV, McCaffery PJ. High expression of retinoic acid receptors and synthetic enzymes in the human hippocampus. Brain Struct Funct 217: 473-483 (2012).
61. Olson CR, Mello CV. Significance of vitamin A to brain function, behavior and learning. Mol. Nutr. Food Res. 54: 489-495 (2010).
62. Goodman T, Crandall JE, Nanescu SE, Quadro L, Shearer K, Ross A, et al. Patterning of retinoic acid signaling and cell proliferation in the hippocampus. Hippocampus 22: 2171-2183 (2012).
63. Chiang MY, Misner D, Kempermann G, Schikorski T, Giguere V, Sucov HM, et al. An essential role for retinoid receptors RARbeta and RXRgamma in long-term potentiation and depression. Neuron 21: 1353-1361 (1998).
64. Zaman Z, Roche S, Fielden P, Frost PG, Niriella DC, Cayley AC. Plasma concentrations of vitamins A and E and carotenoids in Alzheimer’s disease. Age Ageing 21: 91-94 (1992).
65. Imdad A, Yakoob MY, Sudfeld C, Haider BA, Black RE, Bhutta ZA. Impact of vitamin A supplementation on infant and childhood mortality. BMC. Public Health 11(3): S20 (2011).
66. Barbosa CC, Ramalho A, de Carvalho PP, Delia LB, Saunders C. Reduction of vitamin A deficiency and anemia in pregnancy after implementing proposed prenatal nutritional assistance. Nutr Hosp 26: 843-850 (2011).
67. Lam HS, Chow CM, Poon WT, Lai CK, Chan KC, Yeung WL, et al. Risk of vitamin A toxicity from candy-like chewable vitamin supplements for children. Pediatrics 118: 820-824 (2006).
68. Duerbeck NB, Dowling DD. Vitamin A: too much of a good thing? Obstet Gynecol Surv 67: 122-128 (2012).
69. Milosch N, Tanriover G, Kundu A, Rami A, Francois JC, Baumkotter F, et al. Holo-APP and G-protein-mediated signaling are required for sAPPalpha-induced activation of the Akt survival pathway. Cell Death Dis 5: e1391 (2014).
70. Hasebe N, Fujita Y, Ueno M, Yoshimura K, Fujino Y, Yamashita T. Soluble beta-amyloid Precursor Protein Alpha binds to p75 neurotrophin receptor to promote neurite outgrowth. PLoS One 8: e82321 (2013).
71. Corrigan F, Vink R, Blumbergs PC, Masters CL, Cappai R, van den Heuvel C. sAPPalpha rescues deficits in amyloid precursor protein knockout mice following focal traumatic brain injury. J Neurochem 122: 208-220 (2012).
72. Fitz NF, Cronican AA, Lefterov I, Koldamova R. Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”. Science 340: 924-c (2013).
73. Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DR, Golde TE, et al. Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”. Science 340: 924-d (2013).
74. Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M, et al. Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”. Science 340: 924-e (2013).
75. Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J, et al. Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”. Science 340: 924-f (2013).
76. Koryakina A, Aeberhard J, Kiefer S, Hamburger M, Kuenzi P. Regulation of secretases by all-trans-retinoic acid. FEBS J 276: 2645-2655 (2009).
77. Colombo A, Wang H, Kuhn PH, Page R, Kremmer E, Dempsey PJ, et al. Constitutive alpha- and beta-secretase cleavages of the amyloid precursor protein are partially coupled in neurons, but not in frequently used cell lines. Neurobiol Dis 49: 137-147 (2013).
78. Wang R, Chen S, Liu Y, Diao S, Xue Y, You X, et al. All-trans retinoic acid reduces BACE1 expression under inflammatory conditions via modulation of NFkappaB signaling. J Biol Chem 290(37): 22532-22542 (2015).
79. Vora M, Karasek MA. Retinoids upregulate phagocytosis by human dermal microvascular endothelial cells. J Cell Physiol 159: 450-456 (1994).
80. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E, et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 113: 1456-1464 (2004).
81. Piaserico S, Conti A, Lo Console F, De Simone C, Prestinari F, Mazzotta A, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol 94: 293-297 (2014).